8-K: Trevi Therapeutics Reports Q1 2024 Financial Results and Provides Clinical Trial Updates

Trevi Therapeutics announced its first quarter 2024 financial results and provided updates on its clinical trials for Haduvio, including reaffirming timelines for key data readouts.

Summary

• Trevi Therapeutics reported a net loss of $10.9 million for the first quarter of 2024, compared to a net loss of $6.4 million for the same period in 2023.
• Research and development expenses increased to $8.8 million in Q1 2024 from $5.0 million in Q1 2023, primarily due to increased clinical trial activity.
• General and administrative expenses rose to $3.1 million in Q1 2024 from $2.6 million in Q1 2023, driven by increased staffing and professional fees.
• The company ended the quarter with $72.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2026.
• Topline data from the Phase 2a RIVER trial for refractory chronic cough and the Human Abuse Potential (HAP) study are expected in the second half of 2024.
• Topline results from the Phase 2b CORAL trial for chronic cough in IPF are expected in the first half of 2025, with a sample size re-estimation planned for the second half of 2024.
• The company's Investigational New Drug (IND) application was cleared by the FDA for a Phase 1b respiratory physiology study in IPF patients, planned to begin in the third quarter of 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the reaffirmation of clinical trial timelines and the extended cash runway, but the increased net loss and expenses temper the overall outlook.

Positives

• The company has a cash runway into 2026, providing financial stability for ongoing clinical trials.
• All sites are activated for the Phase 2a RIVER trial, and enrollment is progressing.
• The IND for the Phase 1b respiratory physiology study has been cleared by the FDA.
• The company is reaffirming guidance for key clinical trial data readouts.
• The company is actively participating in several upcoming industry conferences.

Negatives

• The net loss for Q1 2024 increased to $10.9 million, compared to $6.4 million in the same period of 2023.
• Research and development expenses have increased significantly year-over-year.
• General and administrative expenses have also increased year-over-year.

Risks

• The success of clinical trials is uncertain, and positive data may not predict results in later trials.
• Regulatory authorities' views on clinical trial data and the development path for Haduvio are uncertain.
• The company's ability to fund future operations, including clinical trials, is subject to uncertainties.
• There are risks associated with estimating the company's cash runway and future expenses.

Future Outlook

The company expects topline data from the Phase 2a RIVER trial and the HAP study in the second half of 2024, and topline results from the Phase 2b CORAL trial in the first half of 2025. They also plan to initiate a Phase 1b respiratory physiology study in the third quarter of 2024. The company's cash runway is expected to extend into 2026.

Management Comments

• Jennifer Good, President and CEO of Trevi Therapeutics, stated that she is pleased with the progress across all clinical trials, which remain on track with guidance.
• Management looks forward to reporting data from ongoing trials beginning in the second half of this year.

Industry Context

Trevi Therapeutics is focused on developing treatments for chronic cough in IPF and refractory chronic cough, areas with no approved therapies in the US. The company's dual-mechanism approach is intended to address both central and peripheral causes of cough, potentially offering a differentiated treatment option in a market with significant unmet need.

Comparison to Industry Standards

• Trevi's increased R&D spending is typical for a clinical-stage biotech company advancing multiple trials.
• The company's cash runway into 2026 is a positive sign, as many biotech companies face funding challenges.
• The timelines for data readouts are consistent with industry standards for Phase 2 trials.
• Companies like Bellus Health and Merck are also developing treatments for chronic cough, but Trevi's dual-mechanism approach is a differentiator.
• The lack of approved therapies for chronic cough in IPF and RCC highlights the significant market opportunity for Trevi.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but reassured by the extended cash runway.
• Employees may be impacted by the increased staffing and activities.
• Patients with chronic cough may benefit from the potential development of Haduvio.
• Creditors may be reassured by the company's financial stability.

Next Steps

• The company will continue enrollment in the Phase 2b CORAL trial.
• The company will conduct a sample size re-estimation for the Phase 2b CORAL trial in the second half of 2024.
• The company will initiate the Phase 1b respiratory physiology study in the third quarter of 2024.
• The company will report topline data from the Phase 2a RIVER trial and the HAP study in the second half of 2024.
• The company will report topline results from the Phase 2b CORAL trial in the first half of 2025.

Key Dates

Keywords

Trevi Therapeutics, Haduvio, Chronic Cough, Idiopathic Pulmonary Fibrosis, IPF, Refractory Chronic Cough, Clinical Trials, Phase 2a RIVER, Phase 2b CORAL, Human Abuse Potential, HAP, Respiratory Physiology, FDA, Nalbuphine ER